Moderna Reports Successful Trial of Flu Vaccine, Plans More Treatments Ahead
Moderna (MRNA) was the best-performing stock in the S&P 500 as the vaccine maker reported its experimental flu shot met its primary endpoint in a Phase 3 trial.
( 1
min )